Can FLT3 inhibitors overcome resistance in AML?
- 13 March 2008
- journal article
- review article
- Published by Elsevier in Best Practice & Research Clinical Haematology
- Vol. 21 (1) , 13-20
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Phase 1/2 Study of Tandutinib (MLN518) Plus Standard Induction Chemotherapy in Newly Diagnosed Acute Myelogenous Leukemia (AML).Blood, 2006
- A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapyBlood, 2006
- Sunitinib in Patients With Metastatic Renal Cell CarcinomaJAMA, 2006
- Sunitinib malate for the treatment of solid tumours: a review of current clinical dataExpert Opinion on Investigational Drugs, 2006
- A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the diseaseBlood, 2005
- Phase II Evaluation of the Tyrosine Kinase Inhibitor MLN518 in Patients with Acute Myeloid Leukemia (AML) Bearing a FLT3 Internal Tandem Duplication (ITD) Mutation.Blood, 2004
- A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivoBlood, 2002
- CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)Cancer Cell, 2002
- FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant modelBlood, 2002
- The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trialsBlood, 2001